Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Mol Cancer Ther. 2024 Jul 2;23(7):924-938. doi: 10.1158/1535-7163.MCT-23-0471.


Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Consensus
  • Humans
  • Mice
  • National Cancer Institute (U.S.)
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • United States
  • Xenograft Model Antitumor Assays*


  • Antineoplastic Agents